View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 8, 2022

Moderna doses first subjects in Phase III influenza vaccine trial

The trial will assess the safety and immunological non-inferiority of the mRNA-1010 vaccine in adults.

Moderna has dosed the first subjects in a Phase III clinical trial of its seasonal influenza vaccine candidate, mRNA-1010. 

The vaccine candidate encodes for hemagglutinin (HA) glycoproteins of the four influenza strains that the World Health Organization (WHO) recommended to prevent influenza, including influenza A/H1N1, A/H3N2, and influenza B/Yamagata- and B/Victoria-lineages. 

HA is a key influenza surface glycoprotein thought to be a crucial target to elicit wide-ranging protection against influenza.

Furthermore, it is the key target of influenza vaccines that are available presently. 

The randomised, observer-blind trial will assess the safety and immunological non-inferiority of the mRNA-1010 vaccine versus a licenced seasonal influenza vaccine in adults aged 18 years and above. 

Subjects will be randomised into a 1:1 ratio to receive either one dose of mRNA-1010 vaccine or a licenced seasonal influenza vaccine as a comparator.

The company expects to enrol nearly 6,000 adult subjects from Southern Hemisphere countries into the trial.

Moderna CEO Stéphane Bancel said: “We are pleased to begin this Phase III study of our seasonal influenza vaccine candidate, mRNA-1010, our fourth mRNA vaccine candidate to begin a pivotal Phase III study. 

“mRNA-1010 is the first of several influenza vaccine candidates we are developing with the aim of iteratively improving traditional vaccines by inducing broad and robust immune responses. 

“We believe our mRNA platform, with the flexibility and speed of our manufacturing process, is well-positioned to address the significant unmet need in seasonal flu.” 

The company currently has four programmes in late-stage Phase III trials, including its SARS-CoV-2 booster, respiratory syncytial virus (RSV), seasonal flu and cytomegalovirus (CMV) vaccine candidates. 

In May this year, Moderna and non-profit scientific research organisation IAVI announced plans to begin Phase I IAVI G003 trial of a human immunodeficiency virus (HIV) vaccine antigen, mRNA-1644, in Rwanda and South Africa.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena